CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR) Files An 8-K Regulation FD Disclosure
Item 7.01
| Regulation FD Disclosure. |
On April 25, 2017, Capricor Therapeutics, Inc., a Delaware
corporation (the Company), issued a press release announcing
positive six-month results from the randomized Phase I/II HOPE
clinical trial in Duchenne muscular dystrophy. A copy of the
press release is attached hereto as Exhibit 99.1 and is
incorporated by reference into this Item 7.01 of this Current
Report on Form 8-K.
The information contained in this Form 8-K (including Exhibit
99.1 attached hereto) is being furnished and shall not be deemed
to be filed for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section and shall not be
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| 99.1 |
Press Release, titled Capricor Therapeutics Announces Positive Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy, dated April 25, 2017. |
About CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR)
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles. CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR) Recent Trading Information
CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR) closed its last trading session up +0.06 at 3.09 with 63,409 shares trading hands.
